A Great Place to Do Great Things: Developing Game-Changing Technology at Abbott
- Abbott has been named a top employer by SCIENCE, evaluated by 6,950 people in science fields around the world

ABBOTT PARK, Ill., Oct. 19, 2017 /PRNewswire/ -- Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. 

For the 14th year, the journal Science today recognized Abbott on its Top Employers list, which is based on an evaluation of 23 characteristics including financial strength, easy adaptation to change, and a research-driven environment.

At Abbott, scientists develop life-changing technologies that help people live their best lives through good health. From freeing people with diabetes from routine finger sticks1, to building a cardiac device to save lives, to hunting for new virus mutations, every day Abbott employees are doing work that matters.

"Abbott's diverse businesses and product lines open up exciting career opportunities for our scientists across a range of technologies," said John Frels, Ph.D., chair of Abbott's Scientific Governing Board, which oversees the company's senior scientific career track.

"We strive to foster a culture of innovation and collaboration within our teams and in our work with others to gain fresh perspectives and further inspire our scientists to continue to push the boundaries on scientific advancements. This contributes to a strong, vibrant and fulfilling environment for scientists to develop their careers – and supports Abbott's long, successful legacy of scientific achievement and game-changing technology."

Our spirit of innovation and relentless focus on pushing the frontiers of science have allowed our company to thrive for more than 125 years. Today, we're working tirelessly to carry on that great legacy and to address some of healthcare's greatest challenges.

Some of Abbott's latest breakthroughs include:

  • A unified family of innovative next-generation diagnostics systems across lab disciplines that offer more efficiency, flexibility and confidence to health systems, and better help doctors and nurses get the results they need to improve decision-making and patient care.
  • Our revolutionary diabetes technology that replaces blood glucose monitoring, freeing people with diabetes from the pain and hassles of routine fingersticks.
  • Pioneering neuromodulation technology that can transform quality of life for many people who are otherwise unable to find relief from their chronic pain, while also reducing or stabilizing opioid use among patients battling chronic pain conditions.
  • A first-of-its-kind cardiac device that has transformed the treatment of certain kinds of mitral regurgitation (MR) for people who are too frail for open-heart surgery or those who are not candidates for surgery.
  • Groundbreaking research that has helped bring infant formula closer than ever to breast milk.

ABOUT THE 2017 SCIENCE SURVEY

The 2017 Science survey sought to identify the companies with the best reputations as employers. The findings are based on 6,950 completed surveys from readers of Science and other survey invitees. Survey respondents came from North America (65%), Europe (25%) and Asia/Pacific Rim (7%); 94% work in biotechnology, biopharmaceutical and pharmaceutical companies. Here's a complete list of the rankings, which also are available in the Oct. 20, 2017 print edition of Science.

ABOUT ABBOTT

At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world – in nutrition, diagnostics, medical devices and branded generic pharmaceuticals – that create more possibilities for more people at all stages of life.

Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

1 A finger prick test using a blood glucose meter is required during times of rapidly changing glucose levels when interstitial fluid glucose levels may not accurately reflect blood glucose levels or if hypoglycaemia or impending hypoglycaemia is reported by the system or when symptoms do not match the system readings.

Abbott Logo (PRNewsFoto/Abbott)

 

 

SOURCE Abbott

For further information: Media: Scott Stoffel, +1-224-668-5201
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

yesno
accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

yesno